HC Wainwright restated their buy rating on shares of LAVA Therapeutics (NASDAQ:LVTX – Free Report) in a research report released on Friday morning, Benzinga reports. The firm currently has a $6.00 price target on the stock.
Separately, JMP Securities restated a market outperform rating and issued a $6.00 price target on shares of LAVA Therapeutics in a research note on Wednesday, August 23rd.
LAVA Therapeutics Stock Performance
LAVA Therapeutics (NASDAQ:LVTX – Get Free Report) last announced its quarterly earnings data on Thursday, November 16th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.15. LAVA Therapeutics had a negative return on equity of 67.23% and a negative net margin of 557.33%. The company had revenue of $0.05 million for the quarter. Equities research analysts predict that LAVA Therapeutics will post -1.65 earnings per share for the current fiscal year.
Institutional Investors Weigh In On LAVA Therapeutics
A number of large investors have recently added to or reduced their stakes in LVTX. Renaissance Technologies LLC acquired a new position in LAVA Therapeutics in the 4th quarter valued at $66,000. Bank of America Corp DE grew its holdings in LAVA Therapeutics by 20,566.7% in the 1st quarter. Bank of America Corp DE now owns 32,240 shares of the company’s stock valued at $54,000 after buying an additional 32,084 shares in the last quarter. PNC Financial Services Group Inc. grew its holdings in LAVA Therapeutics by 30.0% in the 2nd quarter. PNC Financial Services Group Inc. now owns 65,000 shares of the company’s stock valued at $132,000 after buying an additional 15,000 shares in the last quarter. Finally, Bruce & Co. Inc. acquired a new position in LAVA Therapeutics in the 4th quarter valued at $350,000.
LAVA Therapeutics Company Profile
LAVA Therapeutics N.V., a clinical-stage immuno-oncology company, focuses on developing cancer treatments. The company, through its Gammabody platform, develops a portfolio of novel bispecific antibodies to engage and leverage the potency and precision of gamma delta T cells to elicit an anti-tumor immune response and enhance outcomes for cancer patients.
- Five stocks we like better than LAVA Therapeutics
- What Are Dividend Challengers?
- The most upgraded stocks in November have two things in common
- How to Invest in E-Commerce: A Guide
- Monday.com rocked earnings like it’s the weekend
- Dividend Capture Strategy: What You Need to Know
- Plan to own one retailer? Make it this one
Receive News & Ratings for LAVA Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LAVA Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.